IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

Sarit Assouline,Lilian Amrein,Raquel Aloyz,Versha Banerji,Stephen Caplan,Carolyn Owen,Wanda Hasegawa,Sue Robinson,Sudeep Shivakumar,Anca Prica,Anthea C. Peters,Linda Hagerman,Laura Rodriguez,Tanya Skamene,Lawrence Panasci,Bingshu E. Chen,Annette E. Hay

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

2020

Sarit Assouline
Lilian Amrein
Raquel Aloyz
Versha Banerji
Stephen Caplan
Carolyn Owen
Wanda Hasegawa
Sue Robinson
Sudeep Shivakumar
Anca Prica
Anthea C. Peters
Linda Hagerman
Laura Rodriguez
Tanya Skamene
Lawrence Panasci
Bingshu E. Chen
Annette E. Hay

AbstractBuparlisib is an orally available pan-Class I PI3K inhibitor, that is more potent than idelalisib in vitro. Its distinct toxicities include hyperglycemia, hypertension, and mood disturbance...

Keywords:

Refractory Chronic Lymphocytic Leukemia
Phases of clinical research
Diabetes mellitus
Biomarker (medicine)
Clinical trial
Immunology
Buparlisib
Medicine
Chronic lymphocytic leukemia
Idelalisib
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations